Hemostemix Collaborates with Cardiology Team in the Dominican Republic

Previously Successful

The Canadian biotechnology company Hemostemix (TSXV:HEM; FRA:2VF0) is expanding its collaboration with a cardiology team from the Dominican Republic that has already successfully treated 200 patients with ACP-01 therapy in the past.

The treatments took place at the time as part of a study that was published in the scientific journal ‘Stem Cell Research and Therapy’. The participants were treated for atherosclerosis or enlargement of the heart walls (ischemic and non-ischemic dilated cardiomyopathy).

Patients Report Success of Treatment

These patients reported feeling better, having more energy, showing greater resilience, and experiencing an overall improvement in their quality of life. According to Hemostemix, ACP-01 showed remarkable results, increasing the ejection fraction by up to 47.1% in patients with dilated cardiomyopathy and by up to 27% in patients with ischemic cardiomyopathy, in patients with an ejection fraction of 20% or less.

The experienced heart specialists could now treat up to 110 patients per month. At a cost of $37,000 per ACP unit, the team can treat five times as many patients as currently projected for treatment.

Keywords

Disclaimer

I. Information Function and Disclaimer: GOLDINVEST Consulting GmbH offers editors, agencies, and companies the opportunity to publish comments, analyses, and news on www.goldinvest.de. The content serves exclusively for general information and does not replace individual, professional investment advice. It does not constitute financial analyses or sales offers, nor is it a solicitation to buy or sell securities. Decisions made based on the published information are entirely at your own risk. No contractual relationship arises between GOLDINVEST Consulting GmbH and the readers or users, as our information relates exclusively to the company and not to personal investment decisions.

II. Risk Disclosure: The acquisition of securities involves high risks, which can lead to the total loss of the capital invested. Despite careful research, GOLDINVEST Consulting GmbH and its authors assume no liability for financial losses or for the content’s guarantee regarding timeliness, accuracy, appropriateness, and completeness of the published information. Please also note our further terms of use.

III. Conflicts of Interest: In accordance with §34b WpHG and §48f para. 5 BörseG (Austria), we point out that GOLDINVEST Consulting GmbH, as well as its partners, clients, or employees, hold shares in the aforementioned companies. Furthermore, a consulting or other service agreement exists between these companies and GOLDINVEST Consulting GmbH, and it is possible that GOLDINVEST Consulting GmbH may buy or sell shares of these companies at any time. These circumstances can lead to conflicts of interest, as the aforementioned companies compensate GOLDINVEST Consulting GmbH for its reporting.